STAZZONE PETER (Chief Financial Officer) received a stock award from LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 4/17/2026ACC: 0001493152-26-017857
Officer· Chief Financial Officer
Since Sep 2025
0.00
Net shares
Net seller
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
50K acquired · 50K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
+50K
Price / share
—
Trade value
—
% of position
New position
4/15/2026
0.00→50K
Total
Net shares
+50K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/15/2026 | A · Award | +50K | — | — | New position | 0.00 | 50K |
| Total | +50K | $0.00 | ||||||
Derivative Transactions1
Options to Purchase Common Stock
Direct
Converts to
Common
50K shares
Shares
−50K
Strike price
4.45
Held after
0.00
Exercisable
—
4/15/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Options to Purchase Common Stock Direct | Common50K shares | 4/15/2026 | D · Disposition | −50K | 4.45 | — | 0.00 |